Sol-Gel Technologies Ltd. SLGL · Stock Open Sol-Gel Technologies Ltd. in new tab
Sol-Gel Technologies Ltd. Analysis (SLGL)
Is Sol-Gel Technologies Ltd. a good investment? Sol-Gel Technologies Ltd. (SLGL) is currently trading at 73.00 USD. Market analysts have a consensus price target of 152.50 USD. This suggests a potential upside from current levels.
Earnings Schedule: Sol-Gel Technologies Ltd. is expected to release its next earnings report on Nov. 19, 2026. The market consensus estimate for Forward EPS is -8.37.
Investor FAQ
Does Sol-Gel Technologies Ltd. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Sol-Gel Technologies Ltd.?
Sol-Gel Technologies Ltd. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 19, 2026. The company currently has a trailing EPS of -5.62.
Company Profile
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat olmsted syndrome. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
| Split Date | Split Ratio to 1 |
|---|---|
| May 5, 2025 | 1:10 |
Community Discussion